Meta-analysis to evaluate the safety of the EGF vaccine in patients with advanced lung cancer

Meta-analysis to evaluate the safety of the EGF vaccine in patients with advanced lung cancer

0.00 Avg rating0 Votes
Article ID: iaor2009475
Country: Cuba
Volume: 28
Issue: 2
Start Page Number: 107
End Page Number: 120
Publication Date: May 2007
Journal: Revista de Investigacin Operacional
Authors: , , , , ,
Keywords: statistics: multivariate
Abstract:

In this work we undertook a meta-analysis of pooled data from 6 Clinical Trials of vaccination with Epidermal Growth Factor (EGF) in patients with advanced non small cell lung cancer (NSCLC). We realize a meta-analysis with the objective to evaluate the safety of vaccine. The majority of adverse events found was light and moderate and they weren't always related with the product administered during the study. Vaccination with EGF is safe and influences survival of advanced NSCLC patients, therefore it improves the quality of life in patient with advanced lung cancer.

Reviews

Required fields are marked *. Your email address will not be published.